CVS Health Faces 340B Headwinds, Larger Earnings Risks in 2027, BofA Says

MT Newswires Live10-06 23:26

CVS Health (CVS) faces manageable 340B headwinds in 2026, with larger earnings risks emerging in 2027, BofA Securities said in a Tuesday note.

Analysts estimate total earnings per share risk of about $0.45, with $0.06 of headwinds impacting the business in 2026 and larger risks in 2027.

BofA said headwinds include a growing list of drugmakers requiring claim-level data to approve 340B discounts, a proposed rule that would reduce 340B reimbursement, and lawsuits from a few covered entities alleging CVS is retaining excess 340B spreads.

The proposed reimbursement change could result in a $600 million to $700 million EBIT headwind in 2027, according to the note.

Analysts added, however, that the company has multiple ways to offset these headwinds, including through Aetna margin recovery, continued specialty pharmacy growth, and biosimilar adoption.

BofA reiterated a buy rating on the stock and cut its price objective to $110 from $120.

Price: 85.83, Change: -1.18, Percent Change: -1.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673052017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-06 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673052017","market":"hk","top_or_hot":-1,"title":"CVS Health Faces 340B Headwinds, Larger Earnings Risks in 2027, BofA Says","media":"MT Newswires Live","content":"<html><body><p> CVS Health (CVS) faces manageable 340B headwinds in 2026, with larger earnings risks emerging in 2027, BofA Securities said in a Tuesday note.</p><p>Analysts estimate total earnings per share risk of about $0.45, with $0.06 of headwinds impacting the business in 2026 and larger risks in 2027.</p><p>BofA said headwinds include a growing list of drugmakers requiring claim-level data to approve 340B discounts, a proposed rule that would reduce 340B reimbursement, and lawsuits from a few covered entities alleging CVS is retaining excess 340B spreads.</p><p>The proposed reimbursement change could result in a $600 million to $700 million EBIT headwind in 2027, according to the note.</p><p>Analysts added, however, that the company has multiple ways to offset these headwinds, including through Aetna margin recovery, continued specialty pharmacy growth, and biosimilar adoption.</p><p>BofA reiterated a buy rating on the stock and cut its price objective to $110 from $120.</p><p>Price: 85.83, Change: -1.18, Percent Change: -1.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health Faces 340B Headwinds, Larger Earnings Risks in 2027, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health Faces 340B Headwinds, Larger Earnings Risks in 2027, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-06 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CVS Health (CVS) faces manageable 340B headwinds in 2026, with larger earnings risks emerging in 2027, BofA Securities said in a Tuesday note.</p><p>Analysts estimate total earnings per share risk of about $0.45, with $0.06 of headwinds impacting the business in 2026 and larger risks in 2027.</p><p>BofA said headwinds include a growing list of drugmakers requiring claim-level data to approve 340B discounts, a proposed rule that would reduce 340B reimbursement, and lawsuits from a few covered entities alleging CVS is retaining excess 340B spreads.</p><p>The proposed reimbursement change could result in a $600 million to $700 million EBIT headwind in 2027, according to the note.</p><p>Analysts added, however, that the company has multiple ways to offset these headwinds, including through Aetna margin recovery, continued specialty pharmacy growth, and biosimilar adoption.</p><p>BofA reiterated a buy rating on the stock and cut its price objective to $110 from $120.</p><p>Price: 85.83, Change: -1.18, Percent Change: -1.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0208291251.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2673052017","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2673052017","pubTimestamp":1791300381,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CVS Health  faces manageable 340B headwinds in 2026, with larger earnings risks emerging in 2027, BofA Securities said in a Tuesday note.Analysts estimate total earnings per share risk of about $0.45, with $0.06 of headwinds impacting the business in 2026 and larger risks in 2027.BofA said headwinds include a growing list of drugmakers requiring claim-level data to approve 340B discounts, a proposed rule that would reduce 340B reimbursement, and lawsuits from a few covered entities alleging CVS is retaining excess 340B spreads.The proposed reimbursement change could result in a $600 million to $700 million EBIT headwind in 2027, according to the note.Analysts added, however, that the company has multiple ways to offset these headwinds, including through Aetna margin recovery, continued specialty pharmacy growth, and biosimilar adoption.BofA reiterated a buy rating on the stock and cut its price objective to $110 from $120.Price: 85.83, Change: -1.18, Percent Change: -1.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IHF":"iShares Dow Jones U.S. Health Ca","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4504":"桥水持仓","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","RTH":"零售指数ETF-HOLDRs","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4196":"保健护理服务","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","CVS":"西维斯健康","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4581":"高盛持仓","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4585":"ETF&股票定投概念","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","CVS.AU":"Cervantes Corp Ltd","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC"},"translate_title":"美国银行表示，CVS Health 面临 340B 阻力，2027 年盈利风险更大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IHF":0.6,"CVS.AU":1,"CVS":1,"RTH":0.6},"content_text":"CVS Health (CVS) faces manageable 340B headwinds in 2026, with larger earnings risks emerging in 2027, BofA Securities said in a Tuesday note.Analysts estimate total earnings per share risk of about $0.45, with $0.06 of headwinds impacting the business in 2026 and larger risks in 2027.BofA said headwinds include a growing list of drugmakers requiring claim-level data to approve 340B discounts, a proposed rule that would reduce 340B reimbursement, and lawsuits from a few covered entities alleging CVS is retaining excess 340B spreads.The proposed reimbursement change could result in a $600 million to $700 million EBIT headwind in 2027, according to the note.Analysts added, however, that the company has multiple ways to offset these headwinds, including through Aetna margin recovery, continued specialty pharmacy growth, and biosimilar adoption.BofA reiterated a buy rating on the stock and cut its price objective to $110 from $120.Price: 85.83, Change: -1.18, Percent Change: -1.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673052017","isCrawlerRequest":true}